Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
Kristian Thorlund,1 Eric Druyts,2 Antoine C El Khoury,3 Edward J Mills21Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, 2Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada; 3Merck Sharp and Dohme, Whitehouse Station, NJ, USABackground: Boc...
Saved in:
Main Authors: | El Khoury AC (Author), Druyts E (Author), Thorlund K (Author), Mills EJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
by: Cooper CL, et al.
Published: (2012) -
Boceprevir and telaprevir utilization evaluation for the treatment of chronic hepatitis C
by: P. Marrero-Álvarez, et al.
Published: (2014) -
Telaprevir or Boceprevir for Hepatitis C treatment: a first survey of pharmacoutilization
by: Maurizio eCapuozzo, et al.
Published: (2013) -
Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
by: Borba HHL, et al.
Published: (2017) -
Boceprevir and personalized medicine in hepatitis C virus infection
by: Habersetzer F, et al.
Published: (2012)